Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21191731 | 0.94 | CYP1A2 (0.36) | PRCPCYP1A2 | |
| SCHEMBL24926377 | 0.93 | PRCP (0.40) | PRCPGNAI3GNAO1GNAI1 | |
| SCHEMBL26273797 | 0.93 | PRCP (0.40) | PRCPGNAI3GNAO1GNAI1 | |
| SCHEMBL26775584 | 0.93 | PRCP (0.40) | PRCPGNAI3GNAO1GNAI1 | |
| SCHEMBL23634135 | 0.89 | CCR2 (0.38) | PRCPCYP1A2GNAI3GNAO1GNAI1 | |
| SCHEMBL19787861 | 0.88 | KDM4E (0.33) | PRCPCYP1A2KDM4ENPC1CYP2D6 | |
| SCHEMBL22023689 | 0.87 | CCR2 (0.40) | PRCPCYP1A2GNAI3GNAO1GNAI1 | |
| SCHEMBL19627516 | 0.85 | PRCP (0.35) | PRCPCYP1A2KDM4ENPC1CYP2D6 | |
| SCHEMBL22022347 | 0.82 | CCR2 (0.35) | CYP1A2 | |
| SCHEMBL21180382 | 0.82 | CCR2 (0.35) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11124498-B2 | Compositions and methods for modulating protease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCH, PRKCB | PRCP 2205/4885CYP1A2 4622/4885KDM4E 3104/4885 |
| US-11124498-B2 | Compositions and methods for modulating protease activity | RNASE1, ADAM8, CTRL | PRCP 35/4885CYP1A2 4409/4885KDM4E 3253/4885 |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | RNASE1, ADAM8, CTRL | PRCP 35/4885CYP1A2 4409/4885KDM4E 3253/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | PRCP 863/4885CYP1A2 222/4885KDM4E 1899/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | PRCP 863/4885CYP1A2 222/4885KDM4E 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.